“Dose-modified lenalidomide induces sustained hematological response in patients with intermediate to high risk myelodysplasia” (2010) Mediterranean Journal of Hematology and Infectious Diseases, 2(2), p. e2010012. doi:10.4084/mjhid.2010.012.